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Background: Data on the use of circulating microRNAs (miRNAs) as biomarkers of cardiovascular diseases are
emerging. Little, however, is known on the expression profile of circulating of microRNAs in congenital heart
malformations with a systemic right ventricle that is prone to functional impairment. We aimed to test the
hypothesis that circulating miRNA profile is altered in patients late after atrial switch operation for complete
transposition of the great arteries (TGA) and further explored possible relationships between alteration of
circulating miRNAs and systemic ventricular contractility.
Methods: Circulating miRNA expression profiling of serum samples from 5 patients and 5 healthy controls was
performed. The results were validated in 26 patients and 20 controls using real-time quantitative reverse-transcription
polymerase chain reaction for candidate miRNAs with fold changes >3 by expression profiling. Systemic ventricular
myocardial acceleration during isovolumic contraction (IVA) was determined by colour tissue Doppler
echocardiography.
Results: Compared with controls, patients had significantly lower systemic ventricular IVA (p = 0.002). Of the 23
upregulated miRNAs identified by profiling, 11 were validated to be increased in patients compared with controls:
miR-16, miR-106a, miR-144*, miR-18a, miR-25, miR-451, miR-486-3p, miR-486-5p, miR-505*, let-7e and miR-93. Among
the validated 11 miRNAs, miR-18a (r = −0.45, p = 0.002) and miR-486-5p (r = −0.35, p = 0.018) correlated negatively
with systemic ventricular IVA for the whole cohort.
Conclusions: A distinct serum miRNA expression signature exists in adults with complete TGA after atrial switch
operation, with serum miR-18a and miR-486-5p being associated with systemic ventricular contractility.
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MicroRNAs (miRNAs) are small non-coding single-
stranded RNAs with 19 to 24 nucleotides. These form
complementary pair with specific target mRNAs to
negatively regulate their expression via translational
repression or degradation [1]. While alteration of tissue* Correspondence: xfcheung@hku.hk
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reproduction in any medium, provided the ormiRNA expression has been well documented in malig-
nancies [2,3], the role of miRNA in cardiovascular devel-
opment [4], cardiac remodeling and heart failure [5,6], and
myocardial injury [7] is beginning to be recognized.
In determining the potential role of miRNAs in cardio-
vascular diseases, earlier studies have reported distinct
profiles of differential tissue miRNA expression in human
[8,9] and experimental models of heart failure [6,10].
Further cardiac tissue-based studies have provided evi-
dence of involvement of selective miRNAs in myocardial
hypertrophy [11,12], regulation of cardiac apoptosis
[13], regulation of cytoskeleton of cardiomyocytes andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activation [14,15], all of which contribute to adverse
cardiac remodeling.
Recent studies have shown that miRNAs released into
the blood stream are stable and measurable [16,17]. Im-
portantly, data in human subjects on the use of a signature
circulating miRNAs as novel markers of cardiovascular
diseases are emerging. Elevation of plasma cardiac-specific
miRNA-208a has been shown to be potentially useful for
early diagnosis of myocardial infarction [18], while plasma
miR423-5p has also been found to be increased in heart
failure patients with reduced left ventricular (LV) ejection
fraction [19]. Additionally, a signature circulating miRNA
expression profile has been reported in hypertensive
patients [20]. These encouraging data, albeit limited to
date, provide evidence that circulating miRNAs may be
potential biomarkers of cardiovascular diseases, in par-
ticular LV diseases.
Little, however, is known on the expression profile of
circulating microRNAs in congenital heart malformations
with a systemic right ventricle. In patients with complete
transposition of the great arteries (TGA) after atrial switch
operation, late systemic right ventricular (RV) dysfunction
is well documented [21,22]. There is further evidence to
suggest that deterioration of systemic RV function and
clinical status is progressive [22,23]. In this study, we
tested the hypothesis that the circulating miRNA profile is
altered in patients late after atrial switch operation and
further explored the relationships between alteration of
circulating miRNAs and systemic ventricular contractility.
Methods
Subjects
Twenty-six patients with complete TGA who had under-
gone Mustard or Senning procedure were recruited.
The following demographic and clinical variables were
collected: age at study, associated cardiac abnormalities,
age at and type of operation, duration of follow-up since
surgical repair, and current cardiac medications. Twenty
healthy subjects were recruited as controls. The Institu-
tional Review Board of The University of Hong Kong/
Hospital Authority West Cluster, Hong Kong, approved
the study and all study subjects gave written, informed
consent.
Serum collection and small RNA isolation
Blood obtained by venepuncture was centrifuged at
3000 rpm for 15 minutes immediately after collection.
The centrifuged serum was transferred to another tube
and re-spun once again to remove further debris. The
serum samples were stored at −80°C until assay. Total
RNA was extracted using Trizol LS reagent (Invitrogen,
Carlsbad, California, USA) and miRNeasy Mini Kit (Qiagen,
Hilden, California, USA) according to manufacturer’s in-structions with minor modifications [24]. Briefly, 500 μl
of serum was mixed with 1 ml Trizol LS reagent and
the aqueous phase of the mixture was transferred to a
new tube and centrifuged after addition of chloroform.
1.5 volume of absolute ethanol was added to the aqueous
phase and the mixture was applied into miRNeasy spin
column as per manufacturer’s instructions. RNA was
eluted with 30 μl RNase-free water. The concentration
of RNA was quantified by NanoDrop ND-1000 Spectro-
photometer (Nanodrop, Wilmington, Delaware, USA).
MiRNA profiling
To study differential miRNA expression in TGA patients
post atrial switch operation, we performed miRNA ex-
pression profiling of the serum samples from 5 patients
and 5 age- and sex-matched controls using TaqMan
Low Density Array Human MicroRNA Panel (Applied
Biosystems, CA, USA), which contains >754 well-estab-
lished miRNA assays including the respective reverse-
transcription primers, PCR primers, and TaqMan probe.
These 5 patients had the worst systemic RV function as
assessed by echocardiography. For each array assay,
80 ng/μl serum miRNA was used for the reverse-
transcription reaction with a pool of Megaplex RT
primers. TaqMan-based qPCR profiling was performed
using TaqMan Universal PCR Master Mix (Applied
Biosystems) in ABI PRISM 7900 HT system (Applied
Biosystems) according to the manufacturer’s instruc-
tions. U6 small nuclear RNA in the array was selected
as the internal normalization transcript. The Δ cycle of
threshold (Ct) was calculated by subtracting the averaged
Ct values of U6 from the Ct values of the miRNA of
interest. ΔΔCt was then calculated by subtracting ΔCt
of the control from ΔCt of the sample. Fold change of
the miRNA was calculated by the equation: 2−ΔΔCt. Up-
and down-regulation of miRNAs with fold changes >3
were selected for validation in the entire patient cohort.
Real-time quantitative reverse-transcription polymerase
chain reaction
To validate the findings of miRNA profiling, we measured
the expression levels of differentially expressed miRNAs
using Real-Time Quantitative Reverse-Transcription Poly-
merase Chain Reaction (qRT-PCR) in all of the 26 patients
and 20 controls. SYBR green qRT-PCR assay was used
for individual miRNA quantification [24]. Briefly, 30 ng
of serum RNA was polyadenylated by poly(A) polymer-
ase and reversely transcribed using miScript Reverse
Transcription Kit (Qiagen) according to manufacturer’s
instructions. Real-time qPCR was performed using
miScript SYBR Green PCR Kit (Qiagen) in ABI PRISM
7900 Real-time PCR system (Applied Biosystems). Ampli-
fication was performed with the miScript Universal pri-
mer provided by manufacturer and the miRNA-specific
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for qRT-PCR were listed in Additional file 1: Table S1.
The amplification profile was 95°C for 15 minutes,
followed by 45 cycles of 94°C for 15 seconds, 55°C for
30 seconds, and 70°C for 30 seconds. At the end of the
PCR cycles, melting curve analyses were performed.
The expression levels of miRNAs were normalised to
U6 small nuclear RNA (RNU6B) level [24]. The fold
change of the miRNA was calculated as aforementioned.
Echocardiographic assessment
Transthoracic echocardiography was performed using
the Vivid 7 ultrasound system (General Electric Vingmed
Ultrasound, Horten, Norway). Echocardiographic record-
ings were made in three cardiac cycles and the average
was used for statistical analysis. Offline analyses were
performed using the EchoPAC software (General Electric,
Horten, Norway). Colour tissue Doppler echocardiography
was used to measure the relative load independent
index of systolic function, myocardial acceleration dur-
ing isovolumic contraction (IVA) [25], of the systemic
ventricle. Colour-flow mapping was used for the assess-
ment tricuspid regurgitation and baffle stenosis or leakage
in patients.
Statistical analysis
Data are presented as mean ± standard deviation or me-
dian (range) as specified. Demographic variables and echo-
cardiographic parameters were compared using unpaired
Student’s t test and Fisher’s exact test where appropriate.
Serum miRNA expression levels between patients and
controls were compared using Mann–Whitney test.Table 1 Demographic and clinical characteristics of patients a
Microarray
Patients (n = 5) Controls (n
Age at study (years) 26.5 ± 5.1 24.5 ± 6.3
Gender (M:F) 3:2 3:2
BMI (kg/m2) 19.9 ± 1.5 23.3 ± 3.9
BSA (m2) 1.66 ± 0.09 1.77 ± 0.22
Age at surgery (years) 2.24 ± 2.26 -
Type of operation (Mustard: Senning) 1:4 -
Closure of VSD 2 -
Medical treatment (n) (2) -
- ACEI 2 -
- ARB 2 -
- furosemide 1 -
- spironolactone 1 -
- aspirin 1 -
- digoxin 0 -
ACEI: = angiotensin-converting enzyme inhibitors, ARB: = angiotensin II receptor bloc
quantitative reverse-transcription polymerase chain reaction, VSD: = ventricular septRelationships between logarithmically transformed serum
miRNA levels and systemic ventricular IVA were deter-
mined by Pearson correlation analysis. All p values are
two-sided and a p value < 0.05 was considered statistically
significant. All statistical analyses were performed using
SPSS 16.0 (SPSS Inc., Chicago IL, USA).Results
Subject characteristics
The demographic and clinical characteristics of all sub-
jects are summarized in Table 1. Of the 26 patients, 22
had undergone Senning operation while 4 had Mustard
procedure. Eight patients had closure of an associated
ventricular septal defect. At the time of study, 5 patients
were taking cardiac medications and were in New York
Heart Association functional class II. The remaining 21
patients were in functional class I. There were no signifi-
cant differences in age, sex distribution, and body size
between patients and controls for both the cohort in
the profiling study and the entire cohort included in
the validation part (all p > 0.05).Cardiac status in patients
Tricuspid regurgitation was severe in 1 patient, trivial to
mild in 19, and absent in 6. Mild baffle leak was found
in 1 patient, while mild subpulmonary stenosis was noted
in 2. History of cardiac arrhythmias was documented in 4
patients, with 1 each having sinus node dysfunction, first
degree heart block, atrial flutter, and infrequent ventricular
ectopics. All patients were in sinus rhythm at the time of
study. Compared with controls, patients had significantlynd controls
qRT-PCR validation
= 5) p Patients (n = 26) Controls (n = 20) p
0.60 25.3 ± 3.2 25.0 ± 4.3 0.82
1.0 17:9 11:9 0.82
0.12 21.8 ± 3.3 21.6 ± 3.3 0.84
0.30 1.67 ± 0.14 1.70 ± 0.21 0.57










kers, BMI: = body mass index, BSA: = body surface area, qRT-PCR: = real-time
al defect.
Lai et al. BMC Cardiovascular Disorders 2013, 13:73 Page 4 of 9
http://www.biomedcentral.com/1471-2261/13/73reduced systemic ventricular IVA (1.06 ± 0.42 m/s2 vs
1.45 ± 0.39 m/s2, p = 0.002).Identification of differentially expressed serum miRNAs
in patients
Serum miRNA expression profiling was performed using
serum samples from 5 patients and 5 controls matched
for age and sex (Table 1). The level of RNU6B used for
normalization was similar between patients and controls
(32.3 ± 0.4 vs 32.4 ± 0.5, p = 0.54). The levels of serum
miRNAs differed between patients and controls as illus-
trated in the heat map (Figure 1). One hundred miRNAs
with fold change >1 and RNU6B levels are shown in
Additional file 2: Table S2. Using a 3-fold expression
difference as a cut-off level, 23 miRNAs were found to
be significantly up-regulated and 1 miRNA significantly
down-regulated in patients compared with controls
(Table 2). As miR-505* was expressed only in patients,
the absolute fold-change could not be calculated.Figure 1 Profiling of serum microRNAs in 5 patients after atrial switch
healthy control subjects. miRNAs with fold changes >2 are shown in the
y-axis. Colour scale is shown on the top with green indicating downregulaLarger sample size validation
To validate the profiling results, qRT-PCR was performed
to measure the serum expression levels of the 24 miRNAs
in 26 patients and 20 controls. For the whole cohort, there
was similarly no significant difference in RNU6B level
between patients and controls (28.7 ± 1.3 vs 28.8 ± 1.6,
p = 0.79). Among the 23 up-regulated miRNAs, 11 were
significantly elevated in patients compared with con-
trols: miR-16, miR-106a, miR-144*, miR-18a, miR-25,
miR-451, miR-486-3p, miR-486-5p, miR-505*, let-7e
and miR-93 (Figure 2). However, down-regulation of
miR-494 was not confirmed by qRT-PCR.
Factors associated with up-regulated serum miRNAs
For the whole cohort, IVA correlated negatively with
serum miR-18a (r = −0.45, p = 0.002) and miR-486-5p levels
(r = −0.35, p = 0.018) (Figure 3). Furthermore, serum levels
of miR-18a and miR-486-5p were positively correlated
(r = 0.575, p < 0.001) (Additional file 3: Figure S1). None
of validated miRNAs were associated with baselineoperation for transposition of the great arteries (TGA) and 5
heat map. The expression of miRNA is hierarchically clustered on the
tion and red upregulation.
Table 2 Up- and down-regulated miRNAs as defined by
fold changes >3 by expression profiling in patients
compared with control subjects
MicroRNA MirBase no Average fold change
























* is the notation for some of the miRs.
↑ in patients only’ literally ‘increased in patients only.
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of which correlated with body mass index (r = 0.32, p =
0.03) (Additional file 4: Table S3).
Discussion
The present study demonstrates a distinct serum miRNA
expression signature in adult patients with complete TGA
after atrial switch operation. Expression profiling of cir-
culating miRNA revealed significant upregulation of 23
miRNAs and downregulation of 1 miRNA, while only 11
of the upregulated miRNAs were validated in a larger
patient cohort using qRT-PCR. Importantly, significant
negative correlations were identified between systemic
ventricular IVA, a relative load-independent index of
systemic ventricular contractility, and two miRNAs
miR-18a and miR-486-5p.
There is paucity of data on the expression profile of
circulating microRNAs in congenital heart malformations
with a systemic right ventricle. In the only study publishedto date, Tutarel et al. showed no difference in the levels of
circulating miR-423-5p between adults after atrial repair
of TGA and healthy subjects [26]. To our knowledge,
this is the first study using expression profiling followed
by validation of differentially expressed serum miRNAs to
explore potential alteration of circulating miRNA profile
in patients late after atrial switch operation.
Of the 11 validated miRNAs, several had been reported
to associate with cardiovascular and cerebrovascular
diseases. Up-regulation of peripheral blood let-7e has
been shown in large and small artery stroke, cardio-
embolic stroke and stroke with undetermined causes,
while expression of miR-16, miR-106a, miR-25 and miR-
93 were found to be differentially increased in patients
with small artery stroke only [27]. In hypertensive patients,
plasma expression of let-7e has been demonstrated to
be elevated in profiling studies [20]. In a rodent model
of pulmonary hypertension, miR-451 in lung tissues
showed a strong upregulation in hypoxic samples [28],
while in children with aortic stenosis undergoing aortic
valve replacement, differential upregulation of ventricu-
lar let-7e and miR-93 has been reported [8].
The differentially expressed circulating miRNAs iden-
tified in the present study appear to be involved in bio-
logic processes that are of relevance to our patients:
angiogenesis (miR-16 and miR-18a) [29,30], hypoxia
regulation (let-7e, miR-16, miR106a and miR-93) [31],
and apoptosis and cell cycle control (miR-16) [32,33]. In
this regard, it is worthwhile noting that abnormal myo-
cardial perfusion and reduced coronary flow reserve
[34,35] are well documented in patients after atrial switch
operation. It would also be interesting to determine the
level of vascular endothelial growth factors in patients in
future studies. Our recent finding of increased circulating
annexin A5 lends support to possible increased apoptotic
process in these patients [36] Gene prediction program-
mes [37] identify biological pathways of cardiac signifi-
cance, which include MAPK signaling [38], Wnt signaling
[39], and TGF beta signaling [40].
Progressive systemic RV dysfunction in patients after
Senning and Mustard operation remains an important
issue of concern [21,22]. MicroRNAs may play a role in
LV remodeling process through regulating the gene
networks that modulate cardiomyocyte apoptosis and
myocardial fibrosis [41]. While the precise mechanism
of systemic RV dysfunction remains elusive, our novel
findings of negative relationships between expression of
serum miR-18a and miR-486-5p and systemic ventricular
IVA suggests a possible role of dysregulated microRNAs.
The contractile apparatus of the systemic right ventricle
may potentially be jeopardized by ischaemia [34,35] and
apoptosis [36]. miR-18a has been shown to downregulate
Ataxia Telangiectasia Mutated (ATM) expression and
reduce DNA damage repair ability [42]. Further studies
Figure 2 Validation of serum microRNAs levels in patients and controls. Levels of miRNA expression are normalized to RNU6B level.
Horizontal line represents the median.
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[43]. There are also suggestions that our other validated
candidate miR-486-5p, which is enriched in cardiac and
skeletal muscles, may have a role in modulating cardiac
contractile function [44]. Overexpression of miR-486
has been reported to enhance muscle phosphoinositide-3-
kinse (PI3K)/Akt signaling by reducing the upstream
negative regulator, phosphatase and tensin homolog
(PTEN) [44]. Of relevance is the demonstration of de-
creased cardiac contractility with pharmacological in-
hibition of PTEN and in cardiac muscle specific PTEN
knockout mice [45,46]. Furthermore, chronic overex-
pression of Akt has been shown to cause maladaptive
hypertrophy of the left ventricle with dilation andcontractile dysfunction [47]. Although we have not deter-
mined the levels of brain natriuretic peptide, a biomarker
of ventricular dysfunction, in the present study, we [48]
and others [49] have reported previously the elevation
of brain natriuretic peptide in patients after atrial repair
with impaired systemic RV function.
With regard to the cardiac extracellular matrix, the
cardiomyocyte-derived miR-18a has been reported to
play a role in age-related heart failure through modulation
of matrix protein levels [50]. Transfection of miR-25,
another of our validated miRNA candidate, in cardiac
fibroblast has also been demonstrated to decrease col-
lagen gene expression [51]. Indeed, our recent findings
of increased tumour necrosis factor and absence of
Figure 3 Scatter plots showing negative correlation between systemic ventricular myocardial acceleration during isovolumic
contraction (IVA) and (A) serum miR-18a and (B) miR-486-5p expressions. Closed and open dots represent patients and
controls, respectively.
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thesis in patients with TGA after atrial switch operation
implicate reduced myocardial collagen synthesis [36].
Hence, reduction of matrix tensile strength may be a
cause of progressive RV dilation in post Senning and
Mustard patients.
Taken together, our novel finding of a distinct circulat-
ing miRNA profile sheds light on the pathogenesis of
systemic RV dysfunction in patients after atrial switch
operation from an entirely new perspective. There is no
doubt, however, that the findings are preliminary and that
the molecular mechanisms of upregulation of circulating
miRNAs in our patients require further investigations. In
this regard, inclusion of additional patient cohorts with
subpulmonary right ventricles operating under relatively
normal pressure, as in TGA patients after arterial switch
operation, and increased pressure, as those with severe
pulmonary stenosis, may shed more light on the under-
lying mechanism. Another important limitation of the
present study is that we cannot ascertain the source in our
patients of the upregulated circulating miRNAs, which
may occur as a result of cellular damage or secretion [52].
Nonetheless, De Rosa et al. have recently provided convin-
cing evidence of the cardiac source of circulating miRNAs
associated with acute coronary syndromes [53]. Further-
more, despite the undetermined source, circulating miR
NAs may function as potential paracrine mediator of
cardiovascular disease [54].
Conclusion
In conclusion, the present study provides the first evi-
dence of an altered circulating miRNA expression profile
in adult congenital heart patients with a systemic rightventricle after atrial switch operation. While we have
validated the expression profiling results independently
in a bigger cohort of subjects, these preliminary data
need to be confirmed in a larger clinical population. Given
the demonstrable relationships between serum miR-18a
and miR-486-5p expressions and systemic ventricular
contractility, further studies are warranted to explore
the potential usefulness of circulating miRNAs as bio-
markers for development of systemic RV dysfunction.
Additional files
Additional file 1: Table S1. MiRNA-specific primer sequences for
qRT-PCR.
Additional file 2: Table S2. MiRNAs with fold change > 1 and levels
of RNU6B.
Additional file 3: Figure S1. Scatter plot showing a positive correlation
between serum levels of miR-18a and miR-486-5p.
Additional file 4: Table S3. Correlations between miRNAs and
demographic characteristics and systemic ventricular isovolumic
acceleration.
Competing interests
The author(s) declare that they have no competing interests.
Authors’ contributions
YFC has been involved in design of the study. CTML and PCC recruited the
subjects. CTML and PCC have been involved in echocardiographic data
acquisition. CTML carried out the experiments. EKON provided laboratory
technical help. CTML processed the data. CTML performed the statistical
analysis. YFC and CTML analysed and interpreted the data. YFC and CTML
drafted and edited the manuscript. YFC, CTML, EKON and AK critically revised
the manuscript. YFC supervised the study. All authors have read and agree
to the manuscript as written.
Author details
1Division of Paediatric Cardiology, Department of Paediatrics and Adolescent
Medicine, The University of Hong Kong, Hongkong, China. 2Department of
Lai et al. BMC Cardiovascular Disorders 2013, 13:73 Page 8 of 9
http://www.biomedcentral.com/1471-2261/13/73Surgery, The University of Hong Kong, Hong Kong, China. 3Division of
Paediatric Cardiology, Department of Paediatrics and Adolescent Medicine,
The University of Hong Kong, Queen Mary Hospital, 102, Pokfulam Road,
Hong Kong, China.
Received: 18 April 2013 Accepted: 13 September 2013
Published: 16 September 2013References
1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116:281–297.
2. Reid G, Kirschner MB, van Zandwijk N: Circulating microRNAs: association
with disease and potential use as biomarkers. Crit Rev Oncol Hematol
2011, 80:193–208.
3. Lee YS, Dutta A: MicroRNAs in cancer. Annu Rev Pathol 2009, 4:199–227.
4. Liu N, Olson EN: MicroRNA regulatory networks in cardiovascular
development. Dev Cell 2010, 18:510–525.
5. Wang J, Xu R, Lin F, Zhang S, Zhang G, Hu S, Zheng Z: MicroRNA: novel
regulators involved in the remodeling and reverse remodeling of the
heart. Cardiology 2009, 113:81–88.
6. Divakaran V, Mann DL: The emerging role of microRNAs in cardiac
remodeling and heart failure. Circ Res 2008, 103:1072–1083.
7. Bostjancic E, Zidar N, Glavac D: MicroRNA microarray expression profiling
in human myocardial infarction. Dis Markers 2009, 27:255–268.
8. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu
WT: Altered microRNA expression in human heart disease. Physiol
Genomics 2007, 31:367–373.
9. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A,
Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, Dorn GW 2nd:
Reciprocal regulation of myocardial microRNAs and messenger RNA in
human cardiomyopathy and reversal of the microRNA signature by
biomechanical support. Circulation 2009, 119:1263–1271.
10. Naga Prasad SV, Karnik S: MicroRNAs - regulators of signaling networks in
dilated cardiomyopathy. J Cardiovasc Transl Res 2010, 3:225–234.
11. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML,
Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C,
Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce
CM, Peschle C, Condorelli G: MicroRNA-133 controls cardiac hypertrophy.
Nat Med 2007, 13:613–618.
12. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C: MicroRNAs
are aberrantly expressed in hypertrophic heart: do they play a role in
cardiac hypertrophy? Am J Pathol 2007, 170:1831–1840.
13. Li P: MicroRNAs in cardiac apoptosis. J Cardiovasc Transl Res 2010, 3:219–224.
14. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS: MicroRNA-
155 regulates human angiotensin II type 1 receptor expression in
fibroblasts. J Biol Chem 2006, 281:18277–18284.
15. Romero DG, Plonczynski MW, Carvajal CA, Gomez-Sanchez EP, Gomez-
Sanchez CE: Microribonucleic acid-21 increases aldosterone secretion
and proliferation in H295R human adrenocortical cells. Endocrinology
2008, 149:2477–2483.
16. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li
Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang
J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang
CY: Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res 2008, 18:997–1006.
17. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin
H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut
A: Serum microRNAs are promising novel biomarkers.
PLoS One 2008, 3:e3148.
18. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q: Circulating
microRNA: a novel potential biomarker for early diagnosis of acute
myocardial infarction in humans. Eur Heart J 2010, 31:659–666.
19. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE,
Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res
2010, 106:1035–1039.
20. Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, Ma X, Lau WB, Rong
R, Yu X, Wang B, Li Y, Xiao C, Zhang M, Wang S, Yu L, Chen AF, Yang X,
Cai J: Signature microRNA expression profile of essential hypertension
and its novel link to human cytomegalovirus infection. Circulation 2011,
124:175–184.21. Dos L, Teruel L, Ferreira IJ, Rodriguez-Larrea J, Miro L, Girona J, Albert DC,
Gonçalves A, Murtra M, Casaldaliga J: Late outcome of Senning and
Mustard procedures for correction of transposition of the great arteries.
Heart 2005, 91:652–656.
22. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH,
Utens EM, McGhie J, Bos E, Bogers AJ, Simoons ML: Decline in ventricular
function and clinical condition after Mustard repair for transposition of
the great arteries (a prospective study of 22–29 years). Eur Heart J 2004,
25:1264–1270.
23. Derrick G, Deanfield JE: Decline in ventricular function and clinical
condition after Mustard repair. Eur Heart J 2004, 25:1863–1864.
24. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ:
Differential expression of microRNAs in plasma of patients with
colorectal cancer: a potential marker for colorectal cancer screening. Gut
2009, 58:1375–1381.
25. Vogel M, Schmidt MR, Kristiansen SB, Cheung M, White PA, Sorensen K,
Redington AN: Validation of myocardial acceleration during isovolumic
contraction as a novel noninvasive index of right ventricular
contractility: comparison with ventricular pressure-volume relations in
an animal model. Circulation 2002, 105:1693–1699.
26. Tutarel O, Dangwal S, Bretthauer J, Westhoff-Bleck M, Roentgen P, Anker SD,
Bauersachs J, Thum T: Circulating miR-423_5p fails as a biomarker for
systemic ventricular function in adults after atrial repair for transposition
of the great arteries. Int J Cardiol 2011. Epub ahead of print.
27. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW,
Jeyaseelan K: Expression profile of MicroRNAs in young stroke patients.
PLoS One 2009, 4:e7689.
28. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M,
MacDonald RA, Greig JA, Robertson KE, Masson R, Denby L, Dempsie Y,
Long L, Morrell NW, Baker AH: Dynamic changes in lung microRNA
profiles during the development of pulmonary hypertension due to
chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010,
30:716–723.
29. Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al
Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J,
Prats H, Delsol G, Giuriato S, Meggetto F: Hypoxia-microRNA-16
downregulation induces VEGF expression in anaplastic lymphoma
kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 2011,
25:1882–1890.
30. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, Hofmann WK,
Zeiher AM, Dimmeler S: Members of the microRNA-17-92 cluster exhibit a
cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010,
115:4944–4950.
31. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M: A microRNA component of
the hypoxic response. Cell Death Differ 2008, 15:667–671.
32. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: miR-16
family induces cell cycle arrest by regulating multiple cell cycle genes.
Nucleic Acids Res 2008, 36:5391–5404.
33. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE,
Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ,
Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting
BCL2. Proc Natl Acad Sci U S A 2005, 102:13944–13949.
34. Millane T, Bernard EJ, Jaeggi E, Howman-Giles RB, Uren RF, Cartmill TB,
Hawker RE, Celermajer DS: Role of ischemia and infarction in late right
ventricular dysfunction after atrial repair of transposition of the great
arteries. J Am Coll Cardiol 2000, 35:1661–1668.
35. Singh TP, Humes RA, Muzik O, Kottamasu S, Karpawich PP, Di Carli MF:
Myocardial flow reserve in patients with a systemic right ventricle after
atrial switch repair. J Am Coll Cardiol 2001, 37:2120–2125.
36. Lai CT, Chow PC, Wong SJ, Chan KW, Cheung YF: Circulating annexin A5
levels after atrial switch for transposition of the great arteries:
relationship with ventricular deformation and geometry. PLoS One 2012,
7:e52125.
37. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG:
DIANA-mirPath: Integrating human and mouse microRNAs in pathways.
Bioinformatics 2009, 25:1991–1993.
38. Rose BA, Force T, Wang Y: Mitogen-activated protein kinase signaling in
the heart: angels versus demons in a heart-breaking tale. Physiol Rev
2010, 90:1507–1546.
39. Naito AT, Shiojima I, Komuro I: Wnt signaling and aging-related heart
disorders. Circ Res 2010, 107:1295–1303.
Lai et al. BMC Cardiovascular Disorders 2013, 13:73 Page 9 of 9
http://www.biomedcentral.com/1471-2261/13/7340. Leask A: TGFbeta, cardiac fibroblasts, and the fibrotic response.
Cardiovasc Res 2007, 74:207–212.
41. Shah AM, Mann DL: In search of new therapeutic targets and strategies for
heart failure: recent advances in basic science. Lancet 2011, 378:704–712.
42. Song L, Lin C, Wu Z, Gong H, Zeng Y, Wu J, Li M, Li J: miR-18a impairs
DNA damage response through downregulation of ataxia telangiectasia
mutated (ATM) kinase. PLoS One 2011, 6:e25454.
43. Foster CR, Singh M, Subramanian V, Singh K: Ataxia telangiectasia mutated
kinase plays a protective role in beta-adrenergic receptor-stimulated
cardiac myocyte apoptosis and myocardial remodeling. Mol Cell Biochem
2011, 353:13–22.
44. Small EM, O’Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD,
Richardson JA, Olson EN: Regulation of PI3-kinase/Akt signaling by muscle-
enriched microRNA-486. Proc Natl Acad Sci U S A 2010, 107:4218–4223.
45. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E,
Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L,
Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann
MP, Backx PH, Penninger JM: Regulation of myocardial contractility and
cell size by distinct PI3K-PTEN signaling pathways. Cell 2002, 110:737–749.
46. Zu L, Shen Z, Wesley J, Cai ZP: PTEN inhibitors cause a negative inotropic
and chronotropic effect in mice. Eur J Pharmacol 2011, 650:298–302.
47. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K:
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes
to the transition to heart failure. J Clin Invest 2005, 115:2108–2118.
48. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C,
Schellings MW, Swinnen M, Cleutjens JP, van Zandvoort MA, Heymans S,
Schroen B: MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1
expression in age-related heart failure. Aging Cell 2011, 10:769–779.
49. Chow PC, Cheung EW, Chong CY, Lun KS, Yung TC, Wong KT, Chau AK,
Cheung YF: Brain natriuretic peptide as a biomarker of systemic right
ventricular function in patients with transposition of great arteries after
atrial switch operation. Int J Cardiol 2008 2007, 127:192–197.
50. Vogt M, Kühn A, Wiese J, Eicken A, Hess J, Vogel M: Reduced contractile
reserve of the systemic right ventricle under dobutamine stress is
associated with increased brain natriuretic peptide levels in patients
with complete transposition after atrial repair. Eur J Echocardiogr 2009,
10:691–694.
51. Divakaran V, Adrogue J, Ishiyama M, Entman ML, Haudek S,
Sivasubramanian N, Mann DL: Adaptive and maladptive effects of SMAD3
signaling in the adult heart after hemodynamic pressure overloading.
Circ Heart Fail 2009, 2:633–642.
52. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK,
Johnson JM, Sina JF, Fare TL, Sistare FD, Glaab WE: Plasma MicroRNAs as
sensitive and specific biomarkers of tissue injury. Clin Chem 2009,
55:1977–1983.
53. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM:
Transcoronary concentration gradients of circulating microRNAs.
Circulation 2011, 124:1936–1944.
54. Gupta SK, Bang C, Thum T: Circulating microRNAs as biomarkers and
potential paracrine mediators of cardiovascular disease. Circ Cardiovasc
Genet 2010, 3:484–488.
doi:10.1186/1471-2261-13-73
Cite this article as: Lai et al.: Circulating microRNA expression profile
and systemic right ventricular function in adults after atrial switch
operation for complete transposition of the great arteries. BMC
Cardiovascular Disorders 2013 13:73.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
